Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention: A Nationwide Cohort Study

Cited by (394)

Items 101–200 of 394

1. Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study.
   K. A. Fiedler, R. Byrne, S. Schulz, D. Sibbing, J. Mehilli, T. Ibrahim, M. Maeng, K. Laugwitz, A. Kastrati, N. Sarafoff · 2014 · American Heart Journal
2. Anticoagulation management in nonvalvular atrial fibrillation: current and future directions
   Jelena Kornej, Tatjana Potpara, Gregory Y.H. Lip · 2013 · Polskie Archiwum Medycyny Wewnętrznej
3. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
   Roffi, Marco, Patrono, Carlo, Collet, Jean-Philippe, Mueller, Christian, Valgimigli, Marco, Andreotti, Felicita, Bax, Jeroen J., Borger, Michael A., Brotons, Carlos, Chew, Derek P. et al. · 2016 · European Heart Journal
4. Safety and efficacy of P2Y12inhibitor monotherapy in patients undergoing percutaneous coronary interventions
   Mattía Galli, Davide Capodanno, Felicita Andreotti, Filippo Crea, Dominick Joseph Angiolillo · 2020 · Expert Opinion on Drug Safety
5. Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients in the DIRECT Registry)
   Yohei Sotomi, Akio Hirata, Ryohei Amiya, Tomoaki Kobayashi, Atsushi Hirayama, Yasushi Sakata, Yoshiharu Higuchi · 2019 · The American Journal of Cardiology
6. Antithrombotics
   Freek W.A. Verheugt, Jurriën M. ten Berg, Robert F. Storey, Thomas Cuisset, Christopher Bull Granger · 2019 · Journal of the American College of Cardiology
7. Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study
   Jiesuck Park, Eue‐Keun Choi, Kyungdo Han, You-jung Choi, Euijae Lee, Wonseok Choe, So‐Ryoung Lee, Myung‐Jin Cha, Woo‐Hyun Lim, Jeehoon Kang et al. · 2019 · PLoS ONE
8. Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel.
   M. Rohla, T. Weiss, J. Wojta, A. Niessner, K. Huber · 2015 · European Heart Journal - Cardiovascular Pharmacotherapy
9. Dual antiplatelet and anticoagulant (APAC) heparin proteoglycan mimetic with shear-dependent effects on platelet-collagen binding and thrombin generation
   Jason Chen, C. Verni, A. Jouppila, R. Lassila, S. Diamond · 2018 · Thrombosis Research
10. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Daniel Duerschmied, Johannes Brachmann, Harald Darius, Norbert Frey, Hugo Albert Katus, W. Rottbauer, Andreas Schäfer, Hölger Thiele, Christoph Bode, Uwe Zeymer · 2018 · Clinical Research in Cardiology
11. Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation
    C. Sindet-Pedersen, L. Staerk, M. Lamberts, T. Gerds, J. Berger, Anders Nissen Bonde, Jannik Langtved Pallisgaard, M. L. Hansen, C. Torp-Pedersen, G. Gislason et al. · 2017 · Heart
12. Gastrointestinal bleeding in cardiac patients
    Neena S. Abraham · 2014 · Current Opinion in Gastroenterology
13. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: Design of the MUSICA-2 randomized trial
    Antonia Sambola, José Bruno Montoro Ronsano, Bruno García del Blanco, Nadia Llavero, José A. Barrabés, Fernándo Alfonso, Héctor Bueno, Angel R. Cequier, Antonio Serra, Javier Zueco et al. · 2013 · American Heart Journal
14. Triple Antithrombotic Therapy Is the Independent Predictor for the Occurrence of Major Bleeding Complications: Analysis of Percent Time in Therapeutic Range
    Y. Naruse, A. Sato, T. Hoshi, N. Takeyasu, Y. Kakefuda, Mayu Ishibashi, M. Misaki, D. Abe, K. Aonuma · 2013 · Circulation. Cardiovascular Interventions
15. Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes.
    E. Argulian · 2013 · American Journal of Medicine
16. Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS.
    Wen-Bin Lu, Li-Juan Chen, Yu Wang, Yu-Yu Yao, C. Fu, P. Zuo, G. Ma · 2015 · Contemporary Clinical Trials
17. Rate of anticoagulant use, and factors associated with not prescribing anticoagulant in older Thai adults with non-valvular atrial fibrillation: A multicenter registry.
    Rungroj Krittayaphong, Arintaya Phrommintikul, Pornchai Ngamjanyaporn, Khanchai Siriwattana, Wiwat Kanjanarutjawiwat, Thoranis Chantrarat, Roj Rojjarekampai, Pontawee Kaewcomdee, Patthrapon Sonkhammee · 2019 · PubMed Central
18. Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials)
    A. Martischnig, J. Mehilli, J. Pollak, T. Petzold, A. Fiedler, K. Mayer, S. Schulz-Schüpke, D. Sibbing, S. Massberg, A. Kastrati et al. · 2015 · BioMed Research International
19. Comparison of dual antiplatelet therapy versus oral anticoagulation following transcatheter aortic valve replacement: A retrospective single-center registry analysis.
    E. Holy, Julia Kebernik, A. Allali, Mohamed El-Mawardy, G. Richardt, M. Abdel-Wahab · 2017 · Cardiology Journal
20. Pathophysiology, Diagnosis, and Management of Coronary Artery Disease in the Setting of Atrial Fibrillation
    Georgiana Pintea Bentea, Brahim Berdaoui, Marielle Morissens, Philippe van de Borne, José Castro Rodriguez · 2024 · Journal of the American Heart Association
21. The critical role of platelets in venous thromboembolism: Pathogenesis, clinical status, and emerging therapeutic strategies
    Shuang Liu, Yan Shen, Jiayi Chen, Zheng Ruan, Hua Li, Kankan Wang, Xiaodong Xi, Jian‐Hua Mao · 2025 · Blood Reviews
22. Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation ― The Fushimi AF Registry ―
    Nobutoyo Masunaga, Mitsuru Abe, Hisashi Ogawa, Yuya Aono, Syuhei Ikeda, Kosuke Doi, Yoshimori An, Mitsuru Ishii, Moritake Iguchi, Masahiro Esato et al. · 2018 · Circulation Journal
23. Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis
    Natale Daniele Brunetti, Nicola Maria Tarantino, Luisa De Gennaro, Michele Correale, Francesco Santoro, Matteo Di Biase · 2018 · Open Heart
24. Role of insertable cardiac monitors in anticoagulation therapy in patients with atrial fibrillation at high risk of bleeding
    Daniel A.N. Mascarenhas, Mohammad Umar U. Farooq, Paul Ziegler, Bharat K. Kantharia · 2015 · EP Europace
25. Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulant treatment
    Chao-Feng Chen, Bin Chen, Jue Zhu, Yizhou Xu · 2015 · Herz
26. Management of Antiplatelet Agents and Anticoagulants in Patients with Gastrointestinal Bleeding
    Neena S. Abraham · 2015 · Gastrointestinal Endoscopy Clinics of North America
27. Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting
    Grant William Reed, Christopher Paul Cannon · 2013 · Clinical Cardiology
28. Guía de práctica clínica de la ESC sobre revascularización miocárdica, 2014
    S. Windecker, Philippe Kolh, F. Alfonso, Jean-Philippe Collet, J. Crémer, V. Falk, G. Filippatos, Christian W. Hamm, Stuart J. Head, P. Jüni et al. · 2015
29. The Combination of Oral Anticoagulant and Antiplatelet Therapies: Stay One Step Ahead
    Fabiana Lucà, Simona Giubilato, Stefania Angela Di Fusco, Angelo Leone, Stefano Poli, Carmelo Massimiliano Rao, Annamaria Iorio, Sandro Gelsomino, Domenico Gabrielli, Furio Colivicchi et al. · 2020 · Journal of Cardiovascular Pharmacology and Therapeutics
30. Antithrombotic therapy in atrial fibrillation and stent implantation: treatment or threats by the use of triple or dual antithrombotic therapy
    Kurt Huber, Gregory Y.H. Lip, Francisco R. Marín · 2013 · Thrombosis and Haemostasis
31. Increased Incidence of Angiodysplasia of the Gastrointestinal Tract and Bleeding in Patients with Continuous Flow Left Ventricular Assist Devices (LVADs)
    K. Muthiah, D. Robson, P. Macdonald, A. Keogh, E. Kotlyar, E. Granger, K. Dhital, P. Spratt, P. Jansz, C. Hayward · 2013 · International Journal of Artificial Organs
32. Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS
    Grupo de Trabajo, Stefano Benussi, Anders Ahlsson, Barbara Casadei, Manuel Castellá, Hans-Christoph Diener, J. Hendriks, Países Bajos, Gerhard Hindricks Alemania, A. Manolis et al. · 2017
33. Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF
    Freek W.A. Verheugt, Giuseppe Ambrosio, Dan Atar, Jean‐Pierre Bassand, A. John Camm, Juan Pablo Costabel, David Andrew Fitzmaurice, Laura Illingworth, Samuel Zachary Goldhaber, Shinya Goto et al. · 2019 · The American Journal of Medicine
34. Rehospitalizations Following Primary Percutaneous Coronary Intervention in Patients With ST‐Elevation Myocardial Infarction: Results From a Multi‐Center Randomized Trial
    E. Spitzer, M. Frei, Serge Zaugg, Susanne Hadorn, H. Kelbæk, M. Ostojić, A. Baumbach, D. Tüller, M. Roffi, T. Engstrøm et al. · 2017 · Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease
35. Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    T. Hoshi, A. Sato, A. Nogami, M. Gosho, K. Aonuma · 2017 · Journal of Cardiology
36. Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists
    Sean T. Chen, Manesh R. Patel · 2018 · Progress in Cardiovascular Diseases
37. Antiplatelet Therapy in Patients Requiring Oral Anticoagulation and Undergoing Percutaneous Coronary Intervention
    Lina Manzi, Domenico Florimonte, Imma Forzano, Federica Buongiorno, Luca Sperandeo, Domenico Simone Castiello, Roberta Paolillo, Giuseppe Giugliano, Daniele Giacoppo, Alessandro Sciahbasi et al. · 2024 · Interventional Cardiology Clinics
38. Risk of recurrent stroke in patients with atrial fibrillation treated with oral anticoagulants alone or in combination with anti-platelet therapy
    RAF and RENO-EXTEND Investigators · 2023 · European Stroke Journal
39. Time trends in antithrombotic management of patients with atrial fibrillation treated with coronary stents: Results from TALENT‐AF (The internAtionaL stENT – Atrial Fibrillation study) multicenter registry
    Brian James Potter, Giuseppe Andò, Giovanni Cimmino, Ricardo Ladeiras‐Lopes, Zied Frikah, Xin Yue Chen, Vittorio Virga, Joao Goncalves‐Almeida, A. John Camm, Keith A.A. Fox · 2018 · Clinical Cardiology
40. Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: A retrospective cohort study
    Young Hee Nam, Colleen M Brensinger, Warren B. Bilker, Charles E. Leonard, Scott Eric Kasner, Tilo Großer, Xuanwen Li, Sean Hennessy · 2018 · PLoS ONE
41. Concomitant Use of Antiplatelets and Anticoagulants in Patients with Coronary Heart Disease and Atrial Fibrillation: What Do Recent Clinical Trials Teach Us?
    David H. Lam, Sean M. Bell, Ravi S. Hira · 2018 · Current Atherosclerosis Reports
42. How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
    Benjamin Adam Steinberg, Peter J. Shrader, Sunghee Kim, Laine Elliott Thomas, Gregg C. Fonarow, Jack Ansell, Peter Russell Kowey, Daniel E. Singer, Bernard John Gersh, Kenneth W. Mahaffey et al. · 2016 · American Heart Journal
43. Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting: Searching for the Best Combination
    Hazem Fathy Elewa, Dina Ahmed, Geoffrey D. Barnes · 2016 · Seminars in Thrombosis and Hemostasis
44. Substantial differences in initiation of oral anticoagulant therapy and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings
    Anders Pretzmann Mikkelsen, Morten Lock Hansen, Jonas Bjerring Olesen, Morten Winther Hvidtfeldt, Deniz Karasoy, Steen Husted, Søren Paaske Johnsen, Axel Brandes, Gunnar Gislason, Christian Tobias Torp-Pedersen et al. · 2015 · EP Europace
45. Risk of Bleeding Associated With Nonsteroidal Anti‐inflammatory Drug Use in Patients Exposed to Antithrombotic Therapy: A Case‐Crossover Study
    Morgane Paternoster, O. Steichen, M. Lapeyre-Mestre, T. Blanchon, L. Rossignol, A. Vilcu, Titouan Launay, M. Sarazin, H. Bagheri, C. Conte et al. · 2021 · Journal of clinical pharmacology
46. Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention
    Yuichi Saito, Yoshio Kobayashi · 2018 · Journal of Cardiology
47. Non-vitamin K Antagonist Oral Anticoagulant After Acute Coronary Syndrome: Is There a Role?
    Paul Guedeney, Birgit Vogel, Roxana Mehran · 2018 · Interventional Cardiology Reviews Research Resources
48. Switching, Adverse Effects and Use of Over‐the‐Counter Analgesics among Users of Oral Anticoagulants: A Pharmacy‐based Survey
    M. Hellfritzsch, Lea Maria Rønneberg Hyllested, L. Meegaard, Alexander Wiberg‐Hansen, E. Grove, A. Pottegård · 2017 · Basic & Clinical Pharmacology & Toxicology
49. Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions
    N. Faza, A. Mentias, Akhil Parashar, P. Chaudhury, Amr F. Barakat, S. Agarwal, Siddharth A. Wayangankar, S. Ellis, E. Tuzcu, Samir R. Kapadia · 2017 · Catheterization and cardiovascular interventions
50. Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges
    Raffaele De Caterina, Shinya Goto · 2016 · Vascular Pharmacology
51. Kommentar zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Therapie des akuten Herzinfarkts bei Patienten mit ST-Streckenhebung (STEMI)
    Uwe Zeymer, A. Kastrati, T. Rassaf, K. Scholz, H. Thiele, C. Nienaber · 2013 · Der Kardiologe
52. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome in the real world: Data from the Berlin AFibACS Registry.
    B. Maier, Claire Hegenbarth, H. Theres, R. Schoeller, H. Schuehlen, S. Behrens · 2014 · Cardiology Journal
53. Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial
    Gregory Y.H. Lip, Laura Mauri, Gilles Montalescot, Mick Ozkor, Panagiotis E. Vardas, Philippe Gabríel Steg, Deepak L. Bhatt, Stefan Hans Hohnloser, Corinna Miede, Matias Nordaby et al. · 2019 · American Heart Journal
54. Antithrombotic therapy strategies for atrial fibrillation patients undergoing percutaneous coronary intervention: A systematic review and network meta-analysis
    Xiaoxuan Gong, Shaowen Tang, Jiangjin Li, Xiwen Zhang, Xiaoyi Tian, Shuren Ma · 2017 · PLoS ONE
55. Non-vitamin K oral anticoagulant treatment in elderly patients with atrial fibrillation and coronary heart disease
    Xavier Humbert, Vincent Roule, Mathieu Chequel, Sophie Fédrizzi, Marie Brionne, Véronique Lelong‐Boulouard, Paul Milliez, Joachim Alexandre · 2016 · International Journal of Cardiology
56. Percutaneous coronary intervention and atrial fibrillation: the triple therapy dilemma
    J. Cho, D. Angiolillo · 2015 · Journal of Thrombosis and Thrombolysis
57. Oral Antithrombotic Therapy in Atrial Fibrillation Associated With Acute or Chronic Coronary Artery Disease
    John A. Cairns, Michael Sean McMurtry · 2013 · Canadian Journal of Cardiology
58. Major publications in the critical care pharmacotherapy literature: February 2012 through February 2013.
    Charles J Turck, E. Frazee, Bridgette L. Kram, Mitchell J. Daley, Sarah A Day, D. Horner, C. Lesch, J. Mercer, A. Plewa, P. Herout · 2014 · American Journal of Health-System Pharmacy
59. Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
    Soonil Kwon, Jin‐Hyung Jung, Eue‐Keun Choi, Seung‐Woo Lee, Jiesuck Park, So‐Ryoung Lee, Jeehoon Kang, Kyungdo Han, Kyung Woo Park, Seil Oh et al. · 2021 · Korean Circulation Journal
60. Incidence, predictors and prognostic impact of intracranial bleeding within the first year after an acute coronary syndrome in patients treated with percutaneous coronary intervention
    S. Raposeiras-Roubín, E. Abu-Assi, Berenice Caneiro Queija, R. Cobas-Paz, F. D'Ascenzo, J. P. Henriques, Jorge Saucedo, J. González-Juanatey, S. Wilton, W. Kikkert et al. · 2020 · European heart journal. Acute cardiovascular care
61. Efficacy and Safety of the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Ischemic Heart Disease: A Meta-Analysis of Phase III Randomized Trials
    Linghua Fu, Wengen Zhu, Lin Huang, Jinzhu Hu, Jianyong Ma, Gregory Y.H. Lip, Kui Hong · 2018 · American Journal of Cardiovascular Drugs
62. Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention
    Manan Pareek, Deepak L. Bhatt, Jurriën M. ten Berg, Steen Dalby Kristensen, Erik Lerkevang Grove · 2017 · Expert Opinion on Pharmacotherapy
63. Particularities of coronary physiology in patients with atrial fibrillation: insights from combined pressure and flow indices measurements
    Georgiana Pintea Bentea, Brahim Berdaoui, Sophie Samyn, Marielle Morissens, Philippe van de Borne, José Castro Rodriguez · 2023 · Frontiers in Cardiovascular Medicine
64. VE-1902—A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis
    Mohanram Sivaraja, Daniel M. Clemens, Sivan Sizikov, Subhadra Dash, Chengpei Xu, Matthew Rienzo, Bo Yang, Molly R. Ryan, Madhuri Chattopadhyay, Lev Igoudin et al. · 2020 · Thrombosis Research
65. Vitamin K antagonist vs direct oral anticoagulants with antiplatelet therapy in dual or triple therapy after percutaneous coronary intervention or acute coronary syndrome in atrial fibrillation: Meta‐analysis of randomized controlled trials
    Vincent Roule, Pierre Ardouin, Clément Briet, Adrien Lemaître, Mathieu Bignon, Rémi Sabatier, Laure Champ‐Rigot, Paul Milliez, Katrien Blanchart, Farzin Beygui · 2019 · Clinical Cardiology
66. Safety and Efficacy of Low-Dose Prasugrel as Part of Triple Therapy With Aspirin and Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention ― From the TWMU-AF PCI Registry ―
    Hisao Otsuki, Junichi Yamaguchi, Takanori Kawamoto, Masafumi Yoshikawa, Suguru Ebihara, Kazuki Tanaka, Masashi Nakao, Kentaro Jujo, Hiroyuki Arashi, Yoshimi Ota et al. · 2019 · Circulation Journal
67. The Role of Direct Oral Anticoagulants in Patients With Coronary Artery Disease
    Ricky D. Turgeon, Margaret L. Ackman, Hazal E. Babadagli, Jade E. Basaraba, June W. Chen, Mohamed A. Omar, Jian Song Zhou · 2018 · Journal of Cardiovascular Pharmacology and Therapeutics
68. Efficacy and safety of triple versus dual antithrombotic therapy in atrial fibrillation and ischemic heart disease: a systematic review and meta-analysis
    Wengen Zhu, Linjuan Guo, Fadi Liu, Rong Wan, Yang Shen, Gregory Y.H. Lip, Kui Hong · 2017 · Oncotarget
69. Triple Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: a Fading Role
    Dimitrios K. Alexopoulos, Panagiotis K. Vlachakis, John P Lekakis · 2017 · Cardiovascular Drugs and Therapy
70. Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice
    Rohan Shah, Manesh R. Patel · 2016 · Therapeutic Advances in Cardiovascular Disease
71. Adequate time in therapeutic INR range using triple antithrombotic therapy is not associated with long-term cardiovascular events and major bleeding complications after drug-eluting stent implantation
    Hirokazu Konishi, Katsumi Miyauchi, Takatoshi Kasai, Shuta Tsuboi, Manabu Ogita, Ryo Naito, Tomotaka Dohi, Hiroshi Tamura, Shinya Okazaki, Hiroyuki Daida · 2016 · Journal of Cardiology
72. Thin strut bare metal stents in patients with atrial fibrillation: Is there still a need for BMS?
    M. Leschke, M. Waliszewski, M. Pons, S. Champin, L. Nait-Saidi, Mok-He-Ang Tay, O. Maskon, Wan Azman Bin Wan Ahmad, Denny Herberger, M. Moulichon et al. · 2016 · Catheterization and cardiovascular interventions
73. A pharmacist’s guide to the 2012 update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy
    M. Ackman, C. Bucci, M. Callaghan, H. Kertland, C. Pharand, P. Robertson, W. Semchuk · 2015 · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
74. Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation
    Mikhail S. Dzeshka, Gregory Y.H. Lip · 2014 · Cardiology Clinics
75. Unanswered Questions in Patients With Concurrent Atrial Fibrillation and Acute Coronary Syndrome
    Daniel S. Ice, Timothy Alan Shapiro, Eric Gnall, Peter Russell Kowey · 2013 · The American Journal of Cardiology
76. Platelet Dysfunction in Thrombosis Patients Treated with Vitamin K Antagonists and Recurrent Bleeding
    P. V. D. van der Meijden, A. C. Bouman, M. Feijge, R. van Oerle, H. Spronk, K. Hamulýak, A. J. ten Cate-Hoek, H. ten Cate, J. Heemskerk · 2013 · PLoS ONE
77. Investigate the Strategy of Using Pharmacogenetics and Pharmacometabonomics to the Personalization of Ticagrelor Antiplatelet Therapy
    Mohammed Ahmed Akkaif, A. Sha'aban, N. Daud, M. Ng, B. Ibrahim · 2020
78. Reliability of Fractional Flow Reserve and Instantaneous Wave-Free Ratio in Assessing Intermediate Coronary Stenosis in Patients With Atrial Fibrillation.
    Georgiana Pintea Bentea, Brahim Berdaoui, Sophie Samyn, M. Morissens, J. C. Rodriguez · 2021 · American Journal of Cardiology
79. Guidelines for mono, double and triple antithrombotic therapy
    Renate C. A. E. van Uden, I. Houtenbos, A. Griffioen-Keijzer, Diego A. M. Odekerken, P. Van Den Bemt, M. Becker · 2021 · Postgraduate medical journal
80. Novel Oral Anticoagulants Following Percutaneous Coronary Intervention
    Bryan Q. Abadie, Christopher Paul Cannon, Matthew Aaron Cavender · 2020 · Circulation Cardiovascular Interventions
81. OVERVIEW OF NON-VITAMIN K ORAL ANTICOAGULANTS
    I. Cirstea · 2020 · FARMACIA
82. Dual Anti-Thrombotic Therapy With Dabigatran After Percutaneous Coronary Intervention in Atrial Fibrillation ― Japanese and East-Asian Subgroup Analysis of the RE-DUAL PCI Trial ―
    Junya Ako, Ken Okumura, Kōichi Nakao, Ken Kozuma, Yoshihiro Morino, Kotaro Okazaki, Taku Fukaya, Takeshi Kimura, on behalf of the RE-DUAL PCI Trial Investigators · 2019 · Circulation Journal
83. Managing Antithrombotic Agents in the Setting of Acute Gastrointestinal Bleeding.
    M. Kyaw, F. Chan · 2018 · Gastrointestinal Endoscopy Clinics of North America
84. Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis
    Liyao Liu, Jietao Huang, Xiaogang Zhang, Xiaoman Tang · 2018 · PLoS ONE
85. Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks
    Mandeep Singh, Deepak L. Bhatt, Gregg W. Stone, Charanjit S. Rihal, Bernard John Gersh, Ryan J. Lennon, Jagat Narula, Valentı́n Fuster · 2016 · Mayo Clinic Proceedings
86. Patients with atrial fibrillation undergoing percutaneous coronary intervention: current concepts and concerns: part II.
    M. Dzeshka, Richard A. Brown, G. Lip · 2014 · Polskie Archiwum Medycyny Wewnetrznej
87. Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects
    S. Weisshaar, B. Litschauer, G. Gouya, P. Mayer, L. Smerda, S. Kapiotis, P. Kyrle, S. Eichinger, M. Wolzt · 2014 · Journal of Thrombosis and Haemostasis
88. Management of Patients Treated With Oral Anticoagulant Therapy Undergoing Percutaneous Coronary Intervention With Stent Implantation: The PERSEO Registry
    Alessandro Sciahbasi, Salvatore De Rosa, Giuseppe Gargiulo, Daniele Giacoppo, Paolo Calabrò, Giovanni Paolo Talarico, Filippo Zilio, Giuseppe Talanas, Matteo Tebaldi, Giuseppe Andò et al. · 2024 · Journal of Cardiovascular Pharmacology
89. Platelet-targeted thromboprophylaxis with a human serum albumin fusion drug: Preventing thrombosis and reducing cardiac ischemia/reperfusion injurywithout bleeding complications
    Yuyang Song, Laura A. Bienvenu, Viktoria Bongcaron, Shania A Prijaya, Ana C. Maluenda, Aidan P. G. Walsh, James D. McFayden, Geoffrey A. Pietersz, Karlheinz Peter, Xiaowei Wang · 2024 · Theranostics
90. Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
    Jiesuck Park, Jin‐Hyung Jung, Eue‐Keun Choi, Seung‐Woo Lee, Soonil Kwon, So‐Ryoung Lee, Jeehoon Kang, Kyungdo Han, Kyung Woo Park, Seil Oh et al. · 2022 · PLoS ONE
91. Effect of concomitant antiplatelet therapy on ischemic and hemorrhagic events in patients taking oral anticoagulants for nonvalvular atrial fibrillation in daily clinical practice
    T. Morimoto, K. Uchida, Fumihiro Sakakibara, Norito Kinjo, S. Ueda · 2021 · Pharmacoepidemiology and Drug Safety
92. Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome—Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant… Or, Rather, Temporary Dual Antiplatelet Therapy?
    Ugo Limbruno, Francesco De Sensi, Alberto Cresti, Andréa Picchi, Fabio Lena, Raffaele De Caterina · 2020 · Journal of Clinical Medicine
93. Antithrombotic therapy in coronary artery disease patients with atrial fibrillation
    Lili S. Wei, Enyong Su, Weili Liu, Wenlu Xing, Xinyun Liu, You Zhang, Shan Wang, Qianqian Cheng, Datun Qi, Chuanyu Gao · 2020 · BMC Cardiovascular Disorders
94. Concomitant Aspirin and Anticoagulation Is Associated With Increased Risk for Major Bleeding in Surgical Patients Requiring Postoperative Intensive Care*
    Hamza A. A. Rayes, Y. Subat, Timothy J. Weister, Madeline Q Johnson, A. Hanson, Phillip J. Schulte, Vrinda Trivedi, O. Gajic, M. Warner · 2020 · Critical Care Medicine
95. Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats
    Jia Chong, Hao Chen, D. Dai, Shuang-Hu Wang, Quan Zhou, Junpeng Liu, You Lu, Hualan Wu, M. Du, Feifei Chen et al. · 2020 · Pharmaceutical Biology
96. Statement on Antiplatelet Agents and Anticoagulants in Cardiology - 2019
    Carlos Vicente Serrano Junior, Alexandre de Matos Soeiro, Tatiana C Leal, Lucas C. Godoy, Bruno Biselli, Luiz Akira Hata, Eduardo Bruno Martins, Isabela C. K. Abud Manta, Caio A.M. Tavares, Francisco Akira Malta Cardozo et al. · 2019 · Arquivos Brasileiros de Cardiologia
97. Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study
    Vincenzo Russo, Anna Rago, Riccardo Proietti, Emilio Attena, Carmen Rainone, Mario Crisci, Andrea Antonio Papa, Paolo Calabrò, Antonio D’Onofrio, Paolo Golino et al. · 2019 · BioMed Research International
98. Comparison Between Long-Term Clinical Outcomes of Vitamin K Antagonist and Direct Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Ruka Yoshida, I. Morishima, K. Takagi, Yasuhiro Morita, H. Tsuboi, T. Murohara · 2018 · Circulation Journal
99. Value of DAPT score to predict adverse outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: A post-hoc analysis from the AFCAS registry.
    W. Nammas, T. Kiviniemi, A. Schlitt, A. Rubboli, J. Valencia, G. Lip, P. Karjalainen, F. Biancari, K. E. Juhani Airaksinen · 2018 · International Journal of Cardiology
100. Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation
     Mikhail S. Dzeshka, Gregory Y.H. Lip · 2016 · Heart Failure Clinics